Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Rose bengal sodium (Primary)
- Indications Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors Provectus Biopharmaceuticals
- 08 Jul 2016 Status changed from recruiting to completed.
- 24 Nov 2010 As of 24 November 2010, over 40 patients have been enrolled in this compassionate use programme according to a Provectus Pharmaceuticals media release.
- 24 Nov 2010 New trial record